Immune proteomics of Staphylococcus aureus

Proteomics

Volumn 11, Issue 15, 2011, Pages 3221-3231

  Bröker, Barbara M ^a   van Belkum, Alex ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b BIOMÉRIEUX   (France)

Author keywords

Antibodies; Host pathogen interaction; Immune proteomics; Microbiology; Serum proteome approach; Staphylococcus aureus

Indexed keywords

ALTASTAPH; BACTERIUM ANTIBODY; INH A21; STAPHYLOCOCCUS VACCINE; TEFIBAZUMAB; UNCLASSIFIED DRUG; V 710; VERONATE;

ADAPTIVE IMMUNITY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE PROTEOMICS; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGICAL MEMORY; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SPECIES DIVERSITY; STAPHYLOCOCCUS AUREUS; T LYMPHOCYTE;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; HOST-PATHOGEN INTERACTIONS; HUMANS; PROTEOMICS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS AUREUS;

EID: 79960427568     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201100010     Document Type: Review

References (91)

1. Kluytmans, J., van Belkum, A., Verbrugh, H., Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev. 1997, 10, 505-520.
2. Wertheim, H. F. L., Melles, D. C., Vos, M. C., van Leeuwen, W. et al., The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect. Dis. 2005, 5, 751-762.
3. Emonts, M., Uitterlinden, A. G., Nouwen, J. L., Kardys, I. et al., Host polymorphisms in interleukin 4, complement factor H, and C-reactive protein associated with nasal carriage of Staphylococcus aureus and occurrence of boils. J. Infect. Dis. 2008, 197, 1244-1253.
4. van den Akker, E. L., Nouwen, J. L., Melles, D. C., van Rossum, E. F. et al., Staphylococcus aureus nasal carriage is associated with glucocorticoid receptor gene polymorphisms. J. Infect. Dis. 2006, 194, 814-818.
5. Wos-Oxley, M. L., Plumeier, I., von Eiff, C., Taudien, S. et al., A poke into the diversity and associations within human anterior nare microbial communities. ISME J. 2010, 4, 839-851.
6. Iwase, T., Uehara, Y., Shinji, H., Tajima, A. et al., Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature 2010, 465, 346-349.
7. Rooijakkers, S. H., Ruyken, M., Roos, A., Daha, M. R. et al., Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol. 2005, 6, 920-927.
8. Foster, T. J., Immune evasion by staphylococci. Nat. Rev. Microbiol. 2005, 3, 948-958.
9. Witney, A. A., Marsden, G. L., Holden, M. T., Stabler, R. A. et al., Design, validation, and application of a seven-strain Staphylococcus aureus PCR product microarray for comparative genomics. Appl. Environ. Microbiol. 2005, 71, 7504-7514.
10. Melles, D. C., Gorkink, R. F., Boelens, H. A., Snijders, S. V. et al., Natural population dynamics and expansion of pathogenic clones of Staphylococcus aureus. J. Clin. Invest. 2004, 114, 1732-1740.
11. Lindsay, J. A., Genomic variation and evolution of Staphylococcus aureus. Int. J. Med. Microbiol. 2010, 300, 98-103.
12. Lindsay, J. A., Moore, C. E., Day, N. P., Peacock, S. J. et al., Microarrays reveal that each of the ten dominant lineages of Staphylococcus aureus has a unique combination of surface-associated and regulatory genes. J. Bacteriol. 2006, 188, 669-676.
13. Lina, G., Piemont, Y., Godail-Gamot, F., Bes, M. et al., Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin. Infect. Dis. 1999, 29, 1128-1132.
14. Masiuk, H., Kopron, K., Grumann, D., Goerke, C. et al., Association of recurrent furunculosis with Panton-Valentine leukocidin and the genetic background of Staphylococcus aureus. J. Clin. Microbiol. 2010, 48, 1527-1535.
15. Otto, M., Basis of virulence in community-associated methicillin-resistant Staphylococcus aureus. Annu. Rev. Microbiol. 2010, 64, 143-162.
16. Rasigade, J. P., Laurent, F., Lina, G., Meugnier, H. et al., Global distribution and evolution of Panton-Valentine leukocidin-positive methicillin-susceptible Staphylococcus aureus, 1981-2007. J. Infect. Dis. 2010, 201, 1589-1597.
17. Moran, G. J., Krishnadasan, A., Gorwitz, R. J., Fosheim, G. E. et al., Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 2006, 355, 666-674.
18. Deleo, F. R., Otto, M., Kreiswirth, B. N., Chambers, H. F., Community-associated methicillin-resistant Staphylococcus aureus. Lancet 2010, 375, 1557-1568.
19. van Belkum, A., Staphylococcal colonization and infection: homeostasis versus disbalance of human (innate) immunity and bacterial virulence. Curr. Opin. Infect. Dis. 2006, 19, 339-344.
20. te Witt, R., van Belkum, A., van Leeuwen, W. B., Molecular diagnostics and genotyping of MRSA: an update. Exp. Rev. Mol. Diagn. 2010, 10, 375-380.
21. Bode, L. G., Kluytmans, J. A., Wertheim, H. F., Bogaers, D. et al., Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N. Engl. J. Med. 2010, 362, 9-17.
22. Klenk, H. P., Goker, M., En route to a genome-based classification of Archaea and Bacteria? Syst. Appl. Microbiol. 2010, 33, 175-182.
23. Harris, S. R., Feil, E. J., Holden, M. T., Quail, M. A. et al., Evolution of MRSA during hospital transmission and intercontinental spread. Science 2010, 327, 469-474.
24. Ziebandt, A. K., Kusch, H., Degner, M., Jaglitz, S. et al., Proteomics uncovers extreme heterogeneity in the Staphylococcus aureus exoproteome due to genomic plasticity and variant gene regulation. Proteomics 2010, 10, 1634-1644.
25. Pocsfalvi, G., Cacace, G., Cuccurullo, M., Serluca, G. et al., Proteomic analysis of exoproteins expressed by enterotoxigenic Staphylococcus aureus strains. Proteomics 2008, 8, 2462-2476.
26. Becher, D., Hempel, K., Sievers, S., Zühlke, D. et al., A proteomic view of an important human pathogen - towards the quantification of the entire Staphylococcus aureus proteome. PLoS ONE 2009, 4, e8176.
27. Dreisbach, A., Hempel, K., Buist, G., Hecker, M. et al., Profiling the surfacome of Staphylococcus aureus. Proteomics 2010, 10, 3082-3096.
28. Hempel, K., Pane-Farre, J., Otto, A., Sievers, S. et al., Quantitative cell surface proteome profiling for SigB-dependent protein expression in the human pathogen Staphylococcus aureus via biotinylation approach. J. Proteome Res. 2010, 9, 1579-1590.
29. Hecker, M., Becher, D., Fuchs, S., Engelmann, S., A proteomic view of cell physiology and virulence of Staphylococcus aureus. Int. J. Med. Microbiol. 2010, 300, 76-87.
30. Francois, P., Scherl, A., Hochstrasser, D., Schrenzel, J., Proteomic approaches to study Staphylococcus aureus pathogenesis. J. Proteomics 2010, 73, 701-708.
31. Chambers, H. F., Pathogenesis of staphylococcal infection: a manner of expression. J. Infect. Dis. 2009, 199, 291-293.
32. Schmidt, F., Scharf, S. S., Hildebrandt, P., Burian, M. et al., Time-resolved quantitative proteome profiling of host-pathogen interactions: the response of Staphylococcus aureus RN1HG to internalisation by human airway epithelial cells. Proteomics 2010, 10, 2801-2811.
33. Burian, M., Rautenberg, M., Kohler, T., Fritz, M. et al., Temporal expression of adhesion factors and activity of global regulators during establishment of Staphylococcus aureus nasal colonization. J. Infect. Dis. 2010, 201, 1414-1421.
34. Burian, M., Wolz, C., Goerke, C., Regulatory adaptation of Staphylococcus aureus during nasal colonization of humans. PLoS ONE 2010, 5, e10040.
35. Loughman, J. A., Fritz, S. A., Storch, G. A., Hunstad, D. A., Virulence gene expression in human community-acquired Staphylococcus aureus infection. J. Infect. Dis. 2009, 199, 294-301.
36. Holtfreter, S., Kolata, J., Bröker, B. M., Towards the immune proteome of Staphylococcus aureus - the anti-S. aureus antibody response. Int. J. Med. Microbiol. 2010, 300, 176-192.
37. Ohlsen, K., Lorenz, U., Immunotherapeutic strategies to combat staphylococcal infections. Int. J. Med. Microbiol. 2010, 300, 402-410.
38. Rinaudo, C. D., Telford, J. L., Rappuoli, R., Seib, K. L., Vaccinology in the genome era. J. Clin. Invest. 2009, 119, 2515-2525.
39. Mora, M., Telford, J. L., Genome-based approaches to vaccine development. J. Mol. Med. 2010, 88, 143-147.
40. Etz, H., Minh, D. B., Henics, T., Dryla, A. et al., Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl. Acad. Sci. USA 2002, 99, 6573-6578.
41. Weichhart, T., Horky, M., Sollner, J., Gangl, S. et al., Functional selection of vaccine candidate peptides from Staphylococcus aureus whole-genome expression libraries in vitro. Infect. Immun. 2003, 71, 4633-4641.
42. Clarke, S. R., Brummell, K. J., Horsburgh, M. J., McDowell, P. W. et al., Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J. Infect. Dis. 2006, 193, 1098-1108.
43. Vytvytska, O., Nagy, E., Bluggel, M., Meyer, H. et al., Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis. Proteomics 2002, 2, 580-590.
44. Dryla, A., Prustomersky, S., Gelbmann, D., Hanner, M. et al., Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin. Diagn. Lab. Immunol. 2005, 12, 387-398.
45. Albus, A., Fournier, J. M., Wolz, C., Boutonnier, A. et al., Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis. J. Clin. Microbiol. 1988, 26, 2505-2509.
46. Fattom, A., Qualitative and quantitative immune response to bacterial capsular polysaccharides and their conjugates in mouse and man. Adv. Exp. Med. Biol. 1995, 383, 131-139.
47. Karakawa, W. W., Sutton, A., Schneerson, R., Karpas, A., Vann, W. F., Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect. Immun. 1988, 56, 1090-1095.
48. Welch, P. G., Fattom, A., Moore, J., Jr, Schneerson, R. et al., Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis. J. Am. Soc. Nephrol. 1996, 7, 247-253.
49. McKenney, D., Pouliot, K. L., Wang, Y., Murthy, V. et al., Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 1999, 284, 1523-1527.
50. Verkaik, N., Brouwer, E., Hooijkaas, H., van Belkum, A., van Wamel, W., Comparison of carboxylated and Penta-His microspheres for semi-quantitative measurement of antibody responses to His-tagged proteins. J. Immunol. Methods 2008, 335, 121-125.
51. Rucker, V. C., Havenstrite, K. L., Herr, A. E., Antibody microarrays for native toxin detection. Anal. Biochem. 2005, 339, 262-270.
52. Lorenz, U., Ohlsen, K., Karch, H., Hecker, M. et al., Human antibody response during sepsis against targets expressed by methicillin resistant Staphylococcus aureus. FEMS Immunol. Med. Microbiol. 2000, 29, 145-153.
53. Le Marechal, C., Jan, G., Even, S., McCulloch, J. A. et al., Development of serological proteome analysis of mastitis by Staphylococcus aureus in ewes. J. Microbiol. Methods 2009, 79, 131-136.
54. Glowalla, E., Tosetti, B., Krönke, M., Krut, O., Proteomics-based identification of anchorless cell wall proteins as vaccine candidates against Staphylococcus aureus. Infect. Immun. 2009, 77, 2719-2729.
55. Burlak, C., Hammer, C. H., Robinson, M. A., Whitney, A. R. et al., Global analysis of community-associated methicillin-resistant Staphylococcus aureus exoproteins reveals molecules produced in vitro and during infection. Cell Microbiol. 2007, 9, 1172-1190.
56. Lebon, A., Labout, J. A., Verbrugh, H. A., Jaddoe, V. W. et al., Dynamics and determinants of Staphylococcus aureus carriage in infancy: the Generation R Study. J. Clin. Microbiol. 2008, 46, 3517-3521.
57. Lebon, A., Labout, J. A., Verbrugh, H. A., Jaddoe, V. W. et al., Role of Staphylococcus aureus nasal colonization in atopic dermatitis in infants: the Generation R Study. Arch. Pediatr. Adolesc. Med. 2009, 163, 745-749.
58. Fraser, J. D., Proft, T., The bacterial superantigen and superantigen-like proteins. Immunol. Rev. 2008, 225, 226-243.
59. Lappin, E., Ferguson, A. J., Gram-positive toxic shock syndromes. Lancet Infect. Dis. 2009, 9, 281-290.
60. Holtfreter, S., Bauer, K., Thomas, D., Feig, C. et al., egc-Encoded superantigens from Staphylococcus aureus are neutralized by human sera much less efficiently than are classical staphylococcal enterotoxins or toxic shock syndrome toxin. Infect. Immun. 2004, 72, 4061-4071.
61. Holtfreter, S., Roschack, K., Eichler, P., Eske, K. et al., Staphylococcus aureus carriers neutralize superantigens by antibodies specific for their colonizing strain: A potential explanation for their improved prognosis in severe sepsis. J. Infect. Dis. 2006, 193, 1275-1278.
62. Kolata, J., Bode, L. G. M., Holtfreter, S., Steil, L. et al., Distinctive patterns in the human antibody response to Staphylococcus aureus bacteremia in carriers and non-carriers. Proteomics 2011, 11, doi: 10.1002/pmic.201000760.
63. Dryla, A., Prustomersky, S., Gelbmann, D., Hanner, M. et al., Comparison of antibody repertoires against staphylococcus aureus in healthy individuals and in acutely infected patients. Clin. Diagn. Lab. Immunol. 2005, 12, 387-398.
64. Verkaik, N. J., de Vogel, C. P., Boelens, H. A., Grumann, D. et al., Anti-staphylococcal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus aureus. J. Infect. Dis. 2009, 199, 625-632.
65. Jacobsson, G., Colque-Navarro, P., Gustafsson, E., Andersson, R., Mollby, R., Antibody responses in patients with invasive Staphylococcus aureus infections. Eur. J. Clin. Microbiol. Infect. Dis. 2010, 29, 15-25.
66. Verkaik, N. J., Boelens, H. A., de Vogel, C. P., Tavakol, M. et al., Heterogeneity of the humoral immune response following Staphylococcus aureus bacteremia. Eur. J. Clin. Microbiol. Infect. Dis. 2010, 29, 509-518.
67. Holtfreter, S., Nguyen, T. T., Wertheim, H., Steil, L. et al., Human immune proteome in experimental colonization with Staphylococcus aureus. Clin. Vaccine Immunol. 2009, 16, 1607-1614.
68. van Belkum, A., Verkaik, N. J., de Vogel, C. P., Boelens, H. A. et al., Reclassification of Staphylococcus aureus nasal carriage types. J. Infect. Dis. 2009, 199, 1820-1826.
69. Verkaik, N. J., Lebon, A., de Vogel, C. P., Hooijkaas, H. et al., Induction of antibodies by Staphylococcus aureus nasal colonization in young children. Clin. Microbiol. Infect. 2010, 16, 1312-1317.
70. Verkaik, N. J., Dauwalder, O., Antri, K., Boubekri, I. et al., Immunogenicity of toxins during Staphylococcus aureus infection. Clin. Infect. Dis. 2010, 50, 61-68.
71. von Eiff, C., Becker, K., Machka, K., Stammer, H., Peters, G., Nasal Carriage as a source of Staphylococcus aureus bacteremia. N. Engl. J. Med. 2001, 344, 11-16.
72. Wertheim, H. F., Vos, M. C., Ott, A., van Belkum, A. et al., Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004, 364, 703-705.
73. Shinefield, H., Black, S., Fattom, A., Horwith, G. et al., Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med. 2002, 346, 491-496.
74. Haggar, A., Flock, J. I., Norrby-Teglund, A., Extracellular adherence protein (Eap) from Staphylococcus aureus does not function as a superantigen. Clin. Microbiol. Infect. 2010, 16, 1155-1158.
75. Lin, L., Ibrahim, A. S., Xu, X., Farber, J. M. et al., Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 2009, 5, e1000703.
76. Cho, J. S., Pietras, E. M., Garcia, N. C., Ramos, R. I. et al., IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J. Clin. Invest. 2010, 120, 1762-1773.
77. Cook, M. C., Tangye, S. G., Primary immune deficiencies affecting lymphocyte differentiation: lessons from the spectrum of resulting infections. Int. Immunol. 2009, 21, 1003-1011.
78. Bloom, B., Schelonka, R., Kueser, T., Walker, W. et al., Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr. Infect. Dis. J. 2005, 24, 858-866.
79. DeJonge, M., Burchfield, D., Bloom, B., Duenas, M. et al., Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J. Pediatr. 2007, 151, 260-265, e261.
80. Weems, J. J., Jr, Steinberg, J. P., Filler, S., Baddley, J. W. et al., Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 2006, 50, 2751-2755.
81. Benjamin, D. K., Schelonka, R., White, R., Holley, H. P. et al., A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J. Perinatol. 2006, 26, 290-295.
82. Rupp, M. E., Holley, H. P., Jr, Lutz, J., Dicpinigaitis, P. V. et al., Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 2007, 51, 4249-4254.
83. Fattom, A., Fuller, S., Propst, M., Winston, S. et al., Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. Vaccine 2004, 23, 656-663.
84. Fattom, A. I., Horwith, G., Fuller, S., Propst, M., Naso, R., Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine 2004, 22, 880-887.
85. Harro, C., Betts, R., Orenstein, W., Kwak, E. J. et al., Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans. Clin. Vaccine Immunol. 2010, 17, 1868-1874.
86. Kluytmans, J. A. J. W., Wertheim, H. F. L., Nasal carriage of Staphylococcus aureus and prevention of nosocomial infections. Infection 2005, 33, 3-8.
87. Chambers, H. F., Korzeniowski, O. M., Sande, M. A., Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts. Medicine (Baltimore) 1983, 62, 170-177.
88. Grumann, D., Ruotsalainen, E., Kolata, J., Kuusela, P. et al., Characterization of infecting strains and superantigen-neutralizing antibodies in Staphylococcus aureus bacteremia. Clin. Vaccine Immunol. 2011, 18, 487-493.
89. Ruotsalainen, E., Karden-Lilja, M., Kuusela, P., Vuopio-Varkila, J. et al., Methicillin-sensitive Staphylococcus aureus bacteraemia and endocarditis among injection drug users and nonaddicts: host factors, microbiological and serological characteristics. J. Infect. 2008, 56, 249-256.
90. Skurnik, D., Merighi, M., Grout, M., Gadjeva, M. et al., Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice. J. Clin. Invest. 2010, 120, 3220-3233.
91. van Belkum, A., Melles, D. C., Nouwen, J., van Leeuwen, W. B. et al., Co-evolutionary aspects of human colonisation and infection by Staphylococcus aureus. Infect. Genet. Evol. 2009, 9, 32-47.